13-valent pneumococcal conjugate vaccine not checked

Pfizer · 13vPnC · 13-valent Pnumococcal Conjugate vaccine

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 3 trial completes
Trials
2 active
22 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Pneumococcal Diseases, Pneumococcal Disease
Main trialPhase 3
“The purpose of this study is to evaluate a study vaccine called 20-valent pneumococcal conjugate vaccine (20vPnC). The study will assess whether the study vaccine is safe to use in healthy infants. It will also evaluate if the study vaccine can help the body make antibodies (known as immune response). These antibodies help protect against 20 types of pneumococcal bacteria. The study will compare 20vPnC with 13vPnC (control vaccine), which is approved for use in infants. The study is seeking participants who: * Are healthy infants * Aged 42 to 98 days of age at the time of consent. Infants…”In the company’s words, NCT07754539 on ClinicalTrials.gov
Other names
13vPnC · 13-valent Pnumococcal Conjugate vaccine

Other drugs for Pneumococcal Diseases

All 17 drugs for Pneumococcal Diseases

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials22

TrialPhaseCompletesWhat it tests
Phase 3Recruiting 30 Nov 2028 A Study to Evaluate 20vPnC in Healthy Chinese Infants
Phase 1Active, not recruiting 10 Jun 2027 A Study to Understand the Safety of the 20vPnC Vaccine in Healthy Chinese Adults, Children, and Infant
Phase 4Completed 30 Nov 2022 A Study to Describe the Safety of a Vaccine (Called 13vPnC) in Healthy People 18 to 49 Years of Age in India
Phase 3Completed Oct 2009 Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in India
Phase 3Completed 16 Dec 2009 Immune Response In Children Revaccinated With Pneumococcal Conjugate Vaccine
Phase 3Completed 13 Jan 2010 Study Evaluating A 13-Valent Pneumococcal Conjugate Vaccine Administered to Infants in Taiwan
Phase 3Completed 10 Aug 2010 Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Healthy Children Aged 15 Months to 17 Years
Phase 3Completed 1 Aug 2011 Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults
Phase 3Completed Apr 2014 A Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) In Healthy Infants In China
Phase 3Completed 16 Dec 2019 Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults
Phase 3Completed 12 Feb 2020 Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination
Phase 3Completed 23 Aug 2021 A Study Assessing 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Infants and Young Children
Phase 3Completed 2 Apr 2022 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Healthy Japanese Infants
Phase 3Completed 22 Apr 2022 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 3-Dose Series in Healthy Infants
Phase 3Completed 13 May 2022 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Pneumococcal Vaccine-Naïve Adults 60 Years of Age and Older in Japan, Korea, and Taiwan
Phase 3Completed 31 Aug 2022 20-valent Pneumococcal Conjugate Vaccine Safety Study in Healthy Infants
Phase 3Completed 2 Sep 2022 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants
Phase 3Completed 1 Jun 2023 Safety and Immunogenicity of 20vPnC in Toddlers With 2 Prior Doses of Prevenar 13
Phase 3Completed 20 Sep 2025 A Study to Describe the Safety and Immunogenicity of 20vPnC in Infants in India and Taiwan
Phase 2Completed 11 Feb 2020 Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine in Healthy Infants
Phase 1Completed 7 Oct 2022 Safety and Immunogenicity of Pneumococcal Conjugate Formulations in Healthy Adults 18 Through 49 Years of Age
Phase 1Completed 28 Jan 2026 A Study to Learn About How Safe and Effective is 20vPnC and 13vPnC Vaccines in Chinese Adults
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow 13-valent pneumococcal conjugate vaccine

Following is part of Solo: you see every change to 13-valent pneumococcal conjugate vaccine the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in